Palvella Therapeutics stock leapt 33% in a single session, placing it among the top 2% of volume gainers market-wide. The surge drove shares above the 50-day moving average, a level that had contained upside throughout recent trading. This breach signals a potential shift in investor sentiment and may attract momentum traders seeking follow-through buying.